Developer of in vivo gene editing technology for microbiome modulation. The company offers a platform to edit the microbiome's gene repertoire. This platform aims to address diseases triggered or aggravated by specific bacterial genes. The technology targets the interactions between the microbiome and the host's immune system. Founded in 2014, headquartered in Paris, France. The company has raised $52.3M in funding at the series b stage. The team comprises 47 (Jun 30, 2026) employees. Eligo Bioscience operates in the Genomics sector. The company focuses on Gene Editing. Notable investors include Sanofi Ventures, Bpifrance, Khosla Ventures, Seventure Partners, EIC Fund, Europa, among others. The company has a team of 47 employees.
← All startups
Eligo Bioscience
Series BDeveloper of in vivo gene editing technology for microbiome modulation. The company offers a platform to edit the microbiome's gene repertoire. This platform aims to address diseases triggered or aggravated by specific bacterial genes. The technology targets the interactions between the microbiome and the host's immune system. Founded in 2014, headquartered in Paris, France. The company has raised $52.3M in funding…
About
Business model
Genomics > Enabling Technologies > Technology Platforms > Gene Editing
Team background
College Wise > Massachusetts Institute of Technology
Institutional investors
Sanofi VenturesBpifranceKhosla VenturesSeventure PartnersEIC FundEuropaNSG Ventures
Latest coverage
📰 Latest funding news — recent raises and deal signals across the ecosystem.
Backed by funds in our directory
🗂️ Browse all funds in our directory — active VCs and growth investors by stage and sector.